NAVB · Navidea Biopharmaceuticals, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Revenue | $65.7K | $531.5K | $915.0K | $657.8K | $1.17M | $1.81M |
| Cost of Revenue | $1.9K | $0 | $1.0K | $6.7K | $3.7K | - |
| Gross Profit | ($119.3K) | $531.5K | $914.0K | $651.2K | $1.07M | $1.81M |
| R&D | $5.97M | $5.14M | $4.93M | $5.34M | $4.22M | $4.51M |
| SG&A | $7.96M | $7.45M | $6.69M | $6.28M | $7.70M | $11.17M |
| Total Operating Expenses | $13.93M | $12.59M | $11.63M | $11.61M | $11.92M | $15.68M |
| D&A | $48.2K | $36.8K | $33.9K | $103.2K | $120.7K | $232.3K |
| Operating Income | ($14.05M) | ($12.06M) | ($10.71M) | ($10.96M) | ($10.85M) | ($13.88M) |
| Interest Expense | $344.0K | $6.0K | $6.0K | $8.0K | $161.0K | $159.0K |
| Income Tax | $0 | $0 | - | $707 | ($9.8K) | ($4.06M) |
| Net Income | ($11.73M) | ($11.73M) | ($11.39M) | ($10.95M) | ($16.11M) | $74.95M |
| EPS - Basic | ($0.40) | - | - | - | ($0.09) | $0.47 |
| EPS - Diluted | - | - | - | - | ($0.09) | ($0.09) |
Balance Sheet
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.00M | $4.23M | $2.67M | $1.05M | $3.48M | $2.80M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | $427.3K | $151.2K | $169.8K | - | - | - |
| Accounts Payable | $2.12M | $1.42M | $1.16M | $1.11M | $424.7K | $855.0K |
| Current Assets | $3.20M | $5.38M | $6.53M | $2.92M | $5.60M | $13.83M |
| Total Assets | $4.37M | $6.64M | $7.76M | $4.15M | $7.02M | $20.78M |
| Current Liabilities | $9.94M | $5.30M | $4.72M | $3.82M | $3.38M | $8.07M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $12.51M | $6.02M | $5.71M | $5.03M | $4.61M | $8.73M |
| Stockholders' Equity | ($8.44M) | ($106.6K) | $1.32M | ($1.61M) | $1.74M | $11.38M |
| Retained Earnings | ($388.00M) | ($370.79M) | ($359.06M) | ($347.67M) | ($336.72M) | ($319.91M) |
Cash Flow
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($8.99M) | ($10.22M) | ($8.17M) | ($9.35M) | $4.28M | $59.08M |
| Investing Cash Flow | ($390.3K) | ($329.4K) | ($412.8K) | $770.4K | $953.8K | ($1.83M) |
| Financing Cash Flow | $7.14M | $12.11M | $10.21M | $6.16M | ($4.55M) | ($55.99M) |
| CapEx | $63.1K | $25.2K | $135.9K | $1.3K | $46.2K | $33.7K |
| Free Cash Flow | ($9.05M) | ($10.24M) | ($8.31M) | ($9.36M) | $4.23M | $59.05M |
Ratios
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | -181.7% | 100.0% | 99.9% | 99.0% | 91.7% | 99.8% |
| Operating margin | -21402.1% | -2269.1% | -1170.6% | -1666.5% | -927.6% | -766.5% |
| EBITDA margin | -21328.6% | -2262.1% | -1166.9% | -1650.8% | -917.3% | -753.7% |
| Net margin | -17868.3% | -2207.1% | -1244.3% | -1664.3% | -1378.0% | 4139.7% |
| Free cash flow margin | -13784.3% | -1927.2% | -908.1% | -1422.3% | 361.7% | 3261.6% |
| FCF / Net income | 0.77 | 0.87 | 0.73 | 0.85 | -0.26 | 0.79 |
| R&D / Revenue | 9093.1% | 967.4% | 538.8% | 811.5% | 361.0% | 249.3% |
| SG&A / Revenue | 12127.3% | 1401.7% | 731.7% | 954.0% | 658.3% | 617.0% |
| Effective tax rate | - | - | - | - | - | -5.7% |
| Return on assets | -268.3% | -176.5% | -146.8% | -263.8% | -229.5% | 360.6% |
| Return on equity | 139.1% | 11009.2% | -865.4% | 679.0% | -925.0% | 658.6% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 0.32 | 1.02 | 1.38 | 0.76 | 1.66 | 1.71 |
| Quick ratio | 0.28 | 0.99 | 1.35 | 0.76 | 1.66 | 1.71 |
| Cash ratio | 0.20 | 0.80 | 0.57 | 0.27 | 1.03 | 0.35 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -40.8x | -2010.1x | -1785.2x | -1370.3x | -67.4x | -87.3x |
| Equity multiplier | -0.52 | -62.36 | 5.90 | -2.57 | 4.03 | 1.83 |
| Liabilities / Assets | 2.86 | 0.91 | 0.74 | 1.21 | 0.66 | 0.42 |
| Efficiency | ||||||
| Asset turnover | 0.02 | 0.08 | 0.12 | 0.16 | 0.17 | 0.09 |
| Inventory turnover | 0.00 | 0.00 | 0.01 | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | 80361d | - | 59138d | - | - | - |
| Days payable outstanding | 399138d | - | 404606d | 60883d | 42460d | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | -87.6% | -41.9% | 39.1% | -43.7% | -35.4% | -91.8% |
| Revenue CAGR (3y) | -53.6% | -23.1% | -20.3% | -68.9% | -55.5% | -33.9% |
| Revenue CAGR (5y) | -48.5% | -52.5% | -41.4% | -36.3% | 0.7% | 87.2% |
| Gross profit growth (YoY) | - | -41.8% | 40.4% | -39.3% | -40.6% | -90.8% |
| Operating income growth (YoY) | -16.5% | -12.6% | 2.3% | -1.1% | 21.8% | -524.1% |
| Net income growth (YoY) | 0.0% | -3.0% | -4.0% | 32.1% | - | - |
| EPS growth (YoY) | - | - | - | - | 0.0% | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | 11.7% | -23.3% | 11.2% | - | -92.8% | 1561.1% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -7816.8% | - | - | - | -84.7% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Business segments
$531.5K totalDiagnostics Segment$531.5K · 100.0%
Stability scores
Altman Z′
FY 2022 · bankruptcy risk
-86.54
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2022 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- -No share dilution
- ✗Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: In Vitro & In Vivo Diagnostic Substances
Comparing NAVIDEA BIOPHARMACEUTICALS against the 5 most active filers in the same SIC group.